title: Overview of the 2014 Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee meeting about vorapaxar.
authors.affiliation: From the Department of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC.
authors.forename: Nevin C
authors.initials: NC
authors.lastname: Baker
authors.affiliation: From the Department of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC.
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Lipinski
authors.affiliation: From the Department of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC.
authors.forename: Thibault
authors.initials: T
authors.lastname: Lhermusier
authors.affiliation: From the Department of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC. ron.waksman@medstar.net.
authors.forename: Ron
authors.initials: R
authors.lastname: Waksman
mesh_terms: D054058:Acute Coronary Syndrome / Q000517:prevention & control*; D026661:Clinical Trials Data Monitoring Committees; D017277:Drug Approval; D006470:Hemorrhage / Q000453:epidemiology; D006801:Humans; D007783:Lactones / Q000009:adverse effects / Q000627:therapeutic use*; D058226:Plaque, Atherosclerotic / Q000517:prevention & control*; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D011725:Pyridines / Q000009:adverse effects / Q000627:therapeutic use*; D018570:Risk Assessment; D014481:United States
chemical_list: D007783:Lactones; D010975:Platelet Aggregation Inhibitors; D011725:Pyridines; C530299:vorapaxar
keywords: acute coronary syndrome; platelet aggregation inhibitors; thrombolytic therapy